DR. SALVATORE J. BERTOLONE JR., M.D.

Plain English
This study looked at a rare case where a 12-year-old boy experienced a stroke after riding roller coasters at an amusement park. He showed symptoms like facial droop and slurred speech, and doctors found that he had a stroke in the left part of his brain. Fortunately, he was treated with anticoagulants and made a full recovery. This matters because it highlights the potential risks of high-speed amusement park rides for children, who may be more vulnerable to certain injuries due to their developing bodies. Who this helps: This information benefits parents, doctors, and amusement park operators by raising awareness of the risks associated with roller coasters for young riders.

Plain English
This study looked at how long-term erythrocytapheresis (a blood filtering process) affects iron levels in the livers of patients with sickle cell disease. Researchers found that none of the 29 patients had high levels of iron in their hearts, and that there was a strong link between liver iron concentration and serum ferritin levels. Importantly, the number of erythrocytapheresis procedures or blood transfusions did not significantly impact liver iron levels. Who this helps: This helps patients with sickle cell disease who undergo erythrocytapheresis by providing evidence that the procedure may help manage liver iron levels.

Plain English
This study looked at a rare case of spinal cord injury in a 12-year-old girl with a specific blood condition called hemoglobin SC disease after she rode a roller coaster. It found that her injury was likely caused by a blockage of blood flow in her spinal cord due to a fibrocartilaginous embolism, a condition that can happen after activities that put stress on the spine. This is important because it raises awareness that amusement park rides can lead to serious injuries in children with certain health conditions. Who this helps: This helps doctors and parents understand the risks for children with hemoglobin SC disease during amusement park activities.

Plain English
This study looked at a new blood filtering device called the Spectra Optia, which is used to replace red blood cells in patients with sickle cell disease. Researchers tested it in 72 patients, and found that it accurately removed the patient's old red blood cells while keeping the desired amount of new cells in their bloodstream. Importantly, no patients experienced serious side effects, showing that this device is both safe and effective. Who this helps: This benefits patients with sickle cell disease who need red blood cell exchanges.

Plain English
This study looked at a young person with hemoglobin SC disease who experienced serious health problems after a parvovirus infection, ultimately leading to death. An autopsy revealed unusual fat globules in the lungs and brain and showed that parts of the body's bone marrow had died. These findings help identify a rare but serious condition called fat embolism syndrome that can occur in patients with certain blood disorders, emphasizing the importance of recognizing its signs early on. Who this helps: This information benefits doctors and clinicians who treat patients with blood disorders, particularly sickle cell diseases.

Plain English
This study focused on treating 19 young children with a rare and aggressive brain tumor called central nervous system atypical teratoid/rhabdoid tumor (AT/RT). Despite intensive treatment involving surgery, five rounds of chemotherapy, and follow-up care, only four children survived beyond 40 months, while most experienced rapid disease progression and a high rate of death. These findings highlight the urgent need for better treatment options for this challenging condition. Who this helps: This research helps doctors and researchers working with young patients diagnosed with aggressive brain tumors.

Plain English
This study looked at how a treatment called long-term erythrocytapheresis (LTE) affects the growth of children with sickle cell disease (SCD). Researchers found that children who received LTE grew better than those who did not, with weight and height measurements showing significant improvement, and boys achieving their maximum growth height nearly a year earlier than peers who didn’t receive LTE. This matters because it means LTE can help children with SCD grow healthier without the complications of iron overload from other treatments. Who this helps: This helps children with sickle cell disease and their families.

Plain English
This study looked at a young patient with advanced neuroblastoma who developed a dangerous brain infection called cerebral toxoplasmosis after receiving two rounds of high-dose chemotherapy followed by their own stem cell transplant. Toxoplasmosis is a rare but serious risk for patients undergoing this type of treatment, which weakens the immune system more than a single round of chemotherapy. The findings highlight the importance of quickly diagnosing this infection and starting treatment to prevent serious health issues, and they recommend routine testing for a specific antibody in patients undergoing this treatment to help protect those who are at risk. Who this helps: This helps pediatric patients with neuroblastoma and their doctors.

Plain English
This study looked at using a treatment called extracorporeal photopheresis (ECP) for a 12-year-old boy with severe Crohn's disease that didn't improve with standard treatments. After 28 weeks of ECP, the boy showed significant improvement, with his disease symptoms easing and the need for feeding through a tube decreasing. His condition remained stable for at least 16 months after finishing the treatment, making ECP a promising option for kids with difficult-to-treat Crohn's disease. Who this helps: This helps pediatric patients suffering from severe Crohn's disease and their families.

Plain English
This study looked at how well a technique called impedance cardiography (ICG) can detect changes in blood flow and heart function in stable children with sickle cell disease after receiving a treatment called erythrocytapheresis. In 26 children, the researchers found that 28.2% experienced low blood pressure episodes during the procedure, which were linked to smaller body sizes and decreases in heart pumping efficiency. Understanding these changes is crucial for improving the safety and effectiveness of treatments for these patients. Who this helps: This helps children with sickle cell disease and their healthcare providers.

Plain English
This study looked at children with sickle cell disease who received regular blood transfusions to see how matching the blood types affected their immune responses. Researchers found that after starting to match blood types more closely, the rate of important immune reactions (alloimmunization) fell from 0.189 to 0.053 per 100 transfusions, and autoimmunization dropped from 0.063 to 0.035 per 100 transfusions. This is important because reducing these immune responses can make blood transfusions safer for these patients. Who this helps: This benefits children with sickle cell disease and their doctors.

Plain English
This study focused on a condition called neonatal alloimmune thrombocytopenia (NAIT), which affects newborns' blood platelets and can lead to serious bleeding in the brain. Researchers identified a case where NAIT was likely caused by a mother's immune response to a specific type of platelet antigen known as HPA-9b, which is uncommon. Understanding this condition is important because it helps in diagnosing and managing NAIT, potentially preventing serious health issues in newborns. Who this helps: This research helps doctors and improves care for newborns at risk of NAIT.

Plain English
This study looked at how well children with sickle cell disease (SCD) who receive a specific blood treatment called erythrocytapheresis can handle exercise. Researchers tested 16 children and found that 12 of them had lower than expected aerobic capacity, meaning they didn't use oxygen as efficiently during exercise, but all tests were safe and completed without issues. Understanding these exercise limits is important because it helps identify ways to improve the health and activity levels of these children. Who this helps: This helps children with sickle cell disease and their doctors.

Plain English
Researchers studied how a protein called leukemia inhibitory factor (LIF) influences the spread of rhabdomyosarcoma, a type of cancer that often spreads to bone marrow. They found that LIF not only helps the cancer cells move and resist treatments but also allows them to more effectively settle in places like bone marrow and lymph nodes. Specifically, cells responding to LIF were better at spreading to these areas than those responding to another factor, SDF-1, indicating that targeting the LIF pathway could be a new way to limit cancer spread. Who this helps: This information benefits doctors and researchers working to develop new treatments for patients with rhabdomyosarcoma.

Plain English
This study looked at a 2-year-old boy with Hurler syndrome who received both enzyme replacement therapy and a stem cell transplant to reduce complications from the transplant. After the procedures, the boy showed clinical and neurological improvements, and levels of certain substances in his urine decreased. Additionally, the formation of antibodies against the treatment didn’t affect the success of the transplant or the boy's recovery of the important enzyme. Who this helps: This helps patients with Hurler syndrome and their families.

Plain English
This study looked at a device called the Cathlink 20, which helps deliver blood and medication to children with sickle cell disease who need regular blood transfusions. Out of 15 patients, there were only two minor complications from the device, resulting in a very low complication rate of 0.16 for every 1,000 days the device was used. Importantly, there were no serious infections reported, which is a significant improvement compared to other similar devices. Who this helps: This benefits children with sickle cell disease, their families, and the healthcare providers caring for them.

Plain English
This study looked at how long-term blood filtering, called erythrocytapheresis, affects heart function in young patients with sickle cell disease. Researchers found that patients undergoing this treatment had higher levels of a measure called LVMPI, indicating poorer heart function compared to those not receiving the treatment. Specifically, those on long-term treatment had higher LVMPI scores, with significant differences showing that the levels were elevated compared to patients with mild forms of the disease. Who this helps: This research benefits patients with sickle cell disease and their doctors by highlighting potential heart issues associated with blood treatments.

Plain English
This study looked at 32 young patients treated for Hodgkin's disease, a type of cancer, between 1981 and 1992. Most patients were teenagers, and 66% had early-stage cancer, with many having tumors in their necks. The results showed that all patients with early-stage cancer are alive and disease-free, while two patients with advanced stages of the disease unfortunately passed away due to complications. Who this helps: This information helps doctors make better treatment decisions for children and teenagers with Hodgkin's disease.

Plain English
This study looked at how well rituximab, a type of medication, works to treat a serious blood condition called autoimmune hemolytic anemia (AIHA) in a child who had previously received a type of stem cell transplant due to sickle cell disease. The child responded positively to the treatment and improved after receiving rituximab every month. This is important because it shows that rituximab can effectively help patients with AIHA who have undergone stem cell transplants, potentially improving their quality of life. Who this helps: Patients with sickle cell disease and autoimmune hemolytic anemia.

Plain English
This study looked at 15 children with sickle cell disease who were receiving long-term blood treatments to see if their spleens were recovering. Despite significantly lowering the harmful hemoglobin S levels in their blood, none of the children showed improvement in their spleen function. This finding is important because it indicates that simply reducing hemoglobin S doesn't help the spleen recover, which might depend on how intensive the blood treatments are and how long the low levels are maintained. Who this helps: This information benefits doctors and researchers who treat children with sickle cell disease.

Plain English
This study looks at a 7-year-old boy who developed Langerhans cell histiocytosis (LCH) two years after being treated for acute lymphoblastic leukemia (ALL). The findings highlight a potential link between ALL treatment and the development of LCH, raising concerns about long-term effects of chemotherapy. Understanding this connection is important for monitoring and managing the health of childhood cancer survivors. Who this helps: This helps patients and doctors by informing follow-up care for children who have undergone cancer treatment.

Plain English
This study examined the treatment outcomes of pediatric patients with astrocytomas, which are brain tumors, over a ten-year period from 1978 to 1988. Out of 17 patients treated, 63% were still alive after 140 months, with 82% of those with low-grade tumors surviving well without disease. Understanding the impact of tumor grade helps to identify which patients may have better or worse survival chances, guiding future treatment options. Who this helps: This helps doctors and patients by providing insights into treatment effectiveness and survival rates for different types of pediatric astrocytomas.

Plain English
This study looked at the genetic changes in 50 children who relapsed after treatment for acute lymphoblastic leukemia (ALL). Researchers found that most patients had significant changes in their chromosomes, especially with chromosome 1 being affected more often in those with over 50 chromosomes. Understanding these genetic differences helps clarify how the disease evolves and may lead to better treatment strategies. Who this helps: This benefits doctors treating children with leukemia by providing insights into the disease's progression.

Plain English
The study looked at why some members of the American Association for Cancer Education (AACE) are not actively involved, specifically those focused on pediatric oncology. Out of 34 surveyed members, only 19 responded, indicating that while most believed the AACE should provide more educational support and resources for childhood cancer, only 41% felt the organization had a clear role in this area. The findings highlight a need for better collaboration and communication between the AACE and pediatric oncology professionals to improve education and training in this field. Who this helps: This benefits patients and healthcare providers involved in childhood cancer treatment and education.

Plain English
This study looked at how high doses of methotrexate, a chemotherapy drug, affected levels of two amino acids, phenylalanine and tyrosine, in the blood of four young patients with osteosarcoma. The researchers found that after 24 hours of treatment, all the patients showed a significant rise in blood levels of phenylalanine, indicating a problem with a key enzyme involved in processing this amino acid. Notably, one patient who was treated for a long time showed increasing issues over time that standard liver tests did not detect, suggesting ongoing liver damage from the treatment. Who this helps: This helps patients with osteosarcoma and their doctors by providing insights into the effects of chemotherapy on liver health.

Plain English
This study reviewed educational goals for teaching medical students about pediatric cancer developed by a group of experts in 1981. They found that 58 pediatric oncology professionals strongly supported these goals, highlighting that it’s crucial for medical students to learn how to refer children with cancer and manage their treatment and care. The findings suggest that these objectives should be included in medical training programs, ensuring future doctors are well-prepared to support young cancer patients. Who this helps: This benefits medical students and ultimately improves care for children with cancer.

Plain English
This study looked at different types of cancers that can occur in newborns. It found that retinoblastoma is the most common tumor, appearing in about 7% of cases at birth, while other cancers like leukemia can be more aggressive, and neuroblastoma generally has a better outlook. Understanding these cancers is crucial because it can help improve diagnosis and treatment for newborns with cancer. Who this helps: This helps doctors and researchers working with newborn patients.